Last Updated on October 17, 2024 by The Health Master
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg.
Gabapentin tablets are indicated for the management of Postherpetic Neuralgia (PHN).
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.
Gabapentin Tablets had annual sales of $90 million in the United States (IQVIA MAT Dec. 2022).
The group now has 343 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
USFDA gives approval for Saxagliptin Tablets 2.5 mg and 5 mg
USFDA gives tentative nod for these two generic drugs
USFDA gives nod for Aflibercept injection to treat infants with prematurity issue
USFDA gives nod for generic Lenalidomide capsules
USFDA gives approval for Glycopyrrolate Injection USP
USFDA gives approval for Diclofenac Sodium Topical Solution USP
CDSCO gives approval for this Medical Watch
Arunachal Drug Department will soon get 8 more Drug Inspectors
USFDA gives approval for Saxagliptin Tablets 2.5 mg and 5 mg
NPPA proposes ceiling price of 26 more scheduled formulations
USFDA issues Form 483 with 8 observations to Cipla for Pithampur facility
Govt asks Pharma Industry to go for QR code instead of SMS Code
E-pharmacies under radar: Govt to initiate stern action
FDA Haryana: Medical store sealed, drugs being sold at prices higher than MRP
Dissolution test: Importance in Pharma Industry
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
